An investigational aldose reductase inhibitor (ARI), govorestat is being developed for treating several rare diseases. The NDA is supported by data demonstrating a quick and lasting decline in ...

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its ...

central nervous system (CNS)-penetrant aldose reductase inhibitor (ARI), for the treatment of Classic Galactosemia." According to the Company, "[t]he CRL indicates that the FDA completed its ...

The Company’s lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including Classic ...